Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH

Tudor Investment Corp ET AL reduced its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 74.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,048 shares of the biopharmaceutical company’s stock after selling 145,515 shares during the quarter. Tudor Investment Corp ET AL owned 0.10% of Theravance Biopharma worth $745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of TBPH. AQR Capital Management LLC purchased a new position in Theravance Biopharma in the 1st quarter worth about $101,000. Jane Street Group LLC grew its stake in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 88,540 shares during the period. Geode Capital Management LLC raised its holdings in shares of Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock valued at $9,863,000 after purchasing an additional 3,416 shares during the last quarter. Creative Planning purchased a new position in shares of Theravance Biopharma during the second quarter valued at approximately $139,000. Finally, American Century Companies Inc. lifted its position in Theravance Biopharma by 6.8% during the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 5,794 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on TBPH. BTIG Research reaffirmed a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research report on Friday, March 20th. Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Sunday. HC Wainwright lifted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. TD Cowen increased their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. Finally, Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.33.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $16.23 on Wednesday. Theravance Biopharma, Inc. has a 1-year low of $7.90 and a 1-year high of $21.03. The company’s fifty day simple moving average is $17.32 and its 200-day simple moving average is $16.95. The stock has a market capitalization of $835.68 million, a PE ratio of 8.00 and a beta of 0.17.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.